Click any tag below to further narrow down your results
Links
OpenAI is rolling out ChatGPT Health to all U.S. users over 18 on free and paid plans, letting them link personal data from Apple Health, Epic and other platforms. The feature, tested since January amid rising health queries and a lawsuit over bad advice, still carries a disclaimer against using it for formal diagnosis.
- ChatGPT Health is now available to all US users 18+ across free and paid plans, letting them connect data from Apple Health, Epic, and similar platforms into any chat.
- Health-related queries on ChatGPT have jumped from 230 million to 300 million per week since January testing began.
- OpenAI still disclaims the tool for diagnosis or treatment, a stance relevant to a lawsuit claiming ChatGPT discouraged a Florida pastor from seeing a doctor.
Studies show that medical specialists’ ability to detect lesions in endoscopy drops significantly when AI assistance is removed, and similar trials are underway in software engineering. Experts warn that over-reliance on AI can impair hard-won skills and call for research into ways to preserve human expertise.
- Polish endoscopy specialists' adenoma-detection rate dropped from 28.4% to 22.4% when AI assistance was switched off after they'd grown used to it.
- 70% of US nurses and 77% of physicians already worry AI reliance is eroding their clinical skills.
- Anthropic's trial with 52 software engineers found those who habitually used AI took longer and made more errors solving problems without it.
- Researchers like Yuichi Mori say there's no clear fix yet and want "deskilling" made a top research priority.
OpenEvidence is an AI search tool for doctors that indexes only peer-reviewed journals and clinical guidelines. Clinicians verify their credentials to access aggregated, real-time research from sources like JAMA and NEJM, cutting down on AI hallucinations. The free, ad-supported platform has just closed a $200 million Series C round at a $6 billion valuation.
- OpenEvidence raised $200M just three months after its $210M Series B, hitting a $6B valuation
- It's a credential-gated AI search tool for doctors that only pulls from peer-reviewed sources like JAMA, NEJM, PubMed, CDC and FDA to avoid hallucinations
- It's explicitly not for patients—designed to help doctors stay current on unfamiliar diseases, treatments, or new protocols
- The platform is free and ad-supported